According to Sanofi and Dren Bio, DR-0201 treatment could be used to sustain treatment-free remission in patients with hard ... such as autoreactive CD8 T-cells, which are known to play a role ...

Dren Bio’s lead candidate is DR-01, an antibody designed to deplete T cells, which are known to ... in leukaemia and cytotoxic lymphoma patients in a Phase II trial (NCT05475925), produced ...